Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
216 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Sperimentazione conclusa
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
SVIZZERA
Suisse Alémanique
ZÜRICH
Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax
Universitätsspital Zürich
Institut für diagnostische und interventionelle Radiologie
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease
Institution: Information not provided - DE
GERMANIA
Nordrhein-Westfalen
KÖLN
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - DE
Universitätsklinikum Köln
Zentrum für Palliativmedizin
IRLANDA
County Dublin
DUBLIN
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
University College Dublin
UCD School of Medicine
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
BETTER-B: Studio pragmatico internazionale, multicentrico, randomizzato e controllato sulla mirtazapina per alleviare la dispnea nelle cure palliative e di fine vita - IT
Institution: Information not provided - IT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
The TRISTARDS Trial - ThRombolysIS Therapy for ARDS: A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care Compared With SOC Alone, in Patients With ARDS Triggered by COVID-19 - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial (Phase 2) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Allgemeine Anästhesie und Intensivmedizin
AUSTRIA
WIEN
WIEN
EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study - AT
Allgemeines Krankenhaus der Stadt Wien
Intensivstation 13.i2
AUSTRIA
WIEN
WIEN
DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome) - AT
Allgemeines Krankenhaus der Stadt Wien
Intensivstation 13.i2
AUSTRIA
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
AUSTRIA
WIEN
WIEN
COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial (phase 2)
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
AUSTRIA
WIEN
WIEN
Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications
SMZ Süd - Kaiser-Franz-Josef-Spital
4. Medizinische Abteilung mit Infektions- und Tropenmedizin
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE
Erasme Hospital - ULB
Service de Pneumologie
CANADA
Ontario
TORONTO
A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Mount Sinai Hospital
FINLANDIA
Finland
TURKU
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital
Turku PET CENTRE
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
FRANCIA
BRETAGNE
RENNES
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
CHU de Rennes - Hôpital Pontchaillou
Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
ProCoCo: Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome
CHU de Marseille - Hôpital Nord
Service de réanimation médicale détresses respiratoires - Infections sévères
GERMANIA
Baden-Württemberg
HEIDELBERG
IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Thoraxklinik-Heidelberg gGmbH
Abteilung für Pneumologie und Beatmungsmedizin
GERMANIA
Bayern
GAUTING
IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Asklepios-Fachkliniken München-Gauting
Klinik für Pneumologie
GERMANIA
Nordrhein-Westfalen
ESSEN
IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Universitätsklinikum Essen
GERMANIA
Schleswig-Holstein
LÜBECK
IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Medizinische Klinik III - Pneumologie
GIAPPONE
JAPAN
KUMAMOTO
ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
Saiseikai Kumamoto Hospital
Respiratory Medicine & Surgery
GIAPPONE
JAPAN
KYOTO
ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
University Hospital, Kyoto Prefectural University of Medicine
Department of Anesthesiology
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio IPERPEEP - Pressione positiva di fine espirazione individualizzata guidata dal volume polmonare di fine espirazione nella sindrome da distress respiratorio acuto da moderata a grave.
Institution: Information not provided - IT
ITALIA
LAZIO
ROMA
Effetti della pressione positiva di fine espirazione con e senza sincronizzazione inspiratoria in presenza di sindrome da distress respiratorio da moderata a grave
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica
PAESI BASSI
Noord-Holland
AMSTERDAM
IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC
Afdeling Neurologie
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
Decision Support System to Evaluate VENTilation in ARDS (DeVENT)
Imperial College London, main campus
Imperial College London Headquarters
SPAGNA
Cataluña
L'HOSPITALET DE LLOBREGAT
LORALAM-2020: Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM) - ES
Hospital Universitari de Bellvitge
Servicio de Neumología
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
The TRISTARDS Trial - ThRombolysIS Therapy for ARDS: A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care Compared With SOC Alone, in Patients With ARDS Triggered by COVID-19 - ES
Institution: Information not provided - ES
AUSTRIA
STEIERMARK
GRAZ
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - AT
Medizinische Universität Graz
Klinische Abteilung für Pulmonologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-BASIS: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
INTEGRIS-IPF: A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de pneumologie
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STARSCAPE: A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BI 1305-0014: A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE
Erasme Hospital - ULB
Service de Pneumologie
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis - FR
Institution: Information not provided - FR
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -FR
Institution: Information not provided - FR
FRANCIA
GRAND-EST
NANCY
CURDYS: Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia (phase IV) - FR
CHU de Nancy - Maternité régionale
Maternite Regionale Universitaire - CHU Nancy
FRANCIA
ILE-DE-FRANCE
PARIS
EXCHANGE-IPF: Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulins for Severe Acute Exacerbation of Idiopathic Pulmonary Fibrosis Admitted in ICU: an Open, Randomized, Controlled Trial.
CHU Paris Nord-Val de Seine - Hôpital Xavier Bichat-Claude Bernard
Service de pneumologie A
FRANCIA
ILE-DE-FRANCE
PARIS
EXAFIP : Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial (Phase III)
Groupe hospitalier AP-HP.6 - Hôpital Tenon
Unité Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares
FRANCIA
ILE-DE-FRANCE
PARIS
A Phase I/II, Non Randomized, Monocentric Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-Linked Chronic Granulomatous Disease
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique
FRANCIA
ILE-DE-FRANCE
PARIS
A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique - Rhumatologie
FRANCIA
NOUVELLE AQUITAINE
PESSAC
PIC'IRM : LUNG MRI in the Management of Idiopathic Pulmonary Fibrosis
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service de pneumologie
GERMANIA
Baden-Württemberg
HEIDELBERG
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE-
Thoraxklinik-Heidelberg gGmbH
Abteilung für Pneumologie und Beatmungsmedizin
GERMANIA
Baden-Württemberg
HEIDELBERG
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis -DE-
Institution: Information not provided - DE
GERMANIA
Hamburg
HAMBURG
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - DE
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie
GERMANIA
Hessen
FRANKFURT AM MAIN
gene therapy for X-CGD (X-CGD-Version2): A Phase I/II Gene Therapy Trial for X-CGD With a SIN Gammaretroviral Vector - DE
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
GERMANIA
Hessen
FRANKFURT AM MAIN
Phase I/II G1XCGD.01 Sudy: Phase I/II, Non Randomized, Multicenter, Open-label Study of g1xcgd (Lentiviral Vector Transduced cd34+ Cells) in Patients with X-linked Chronic Granulomatous Disease - DE
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
GERMANIA
Hessen
GIEßEN
Influence of noninvasive positive pressure ventilation versus nasal high-frequency oscillation ventilation on parameters of oxygenation and ventilation in preterm infants in the weaning phase after respiratory distress syndrome
Kinderklinik des UKGM am Standort Gießen
Abteilung für Allgemeine Pädiatrie und Neonatologie
GERMANIA
Hessen
GIEßEN
An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (Phase III) - DE
Med. Klinik und Poliklinik II des UKGM am Standort Gießen
Schwerpunkt Pneumologie und Intensivmedizin - Fibrosierende Lungenerkrankungen
GERMANIA
Hessen
GIEßEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) -DE
Med. Klinik und Poliklinik II des UKGM am Standort Gießen
Schwerpunkt Pneumologie und Intensivmedizin - Fibrosierende Lungenerkrankungen
GERMANIA
Hessen
IMMENHAUSEN
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE-
Lungenfachklinik Immenhausen
Zentrum für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin
GERMANIA
Nordrhein-Westfalen
ESSEN
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE
Universitätsklinikum Essen
GERMANIA
Nordrhein-Westfalen
ESSEN
An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary Fibrosis (Phase IV) - DE
Universitätsmedizin Essen - Ruhrlandklinik
Abteilung für Interventionelle Pneumologie
GERMANIA
Nordrhein-Westfalen
ESSEN
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE-
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
GERMANIA
Nordrhein-Westfalen
ESSEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) -DE
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
GERMANIA
Nordrhein-Westfalen
MÜNSTER
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE
Universitätsklinikum Münster
GERMANIA
Nordrhein-Westfalen
SANKT AUGUSTIN
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - DE
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin
IRLANDA
County Dublin
DUBLIN
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis - IE
St. Vincent's University Hospital
CF Clinic
ITALIA
TOSCANA
FIRENZE
Studio randomizzato, in aperto, multinazionale, multicentrico, suddiviso in due parti nei neonati pretermine con respirazione spontanea con Sindrome da Distress respiratorio da lieve a moderata, volta a valutare la sicurezza, la tollerabilità e l'efficacia di Poractant Alfa (Surfattante porcino, Curosurf®) in confronto con la sola nCPAP
Azienda Ospedaliero Universitaria Careggi
S.O.D. Neonatologia e Terapia Intensiva Neonatale
PAESI BASSI
Gelderland
NIJMEGEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
CWZ - Canisius Wilhelmina Ziekenhuis
PAESI BASSI
Limburg
HEERLEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Zuyderland Medisch Centrum, locatie Heerlen
PAESI BASSI
Noord-Brabant
EINDHOVEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Catharina Ziekenhuis
PAESI BASSI
Noord-Holland
AMSTERDAM
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Amsterdam UMC, locatie VUmc
PAESI BASSI
Utrecht
NIEUWEGEIN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
St. Antonius Ziekenhuis
PAESI BASSI
Utrecht
UTRECHT
Gastrointestinal side effects of MTX in patients with JIA: Phase III effectiveness multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate (MTX) related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of care
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Zuid-Holland
LEIDEN
BeSt for kids: A randomized clinical intervention trial to test the effectiveness of different treatment strategies in patients with Juvenile Idiopathic Arthritis
LUMC - Leids Universitair Medisch Centrum
Willem-Alexander Kinderziekenhuis
PORTOGALLO
SUL
LISBOA
A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis - PT
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
Serviço de Pneumologia
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
Biologics in refractory vasculitis
University of Cambridge
Department of Medicine
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -GB
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
IPF-COMFORT: A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis -GB
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
REGNO UNITO; GRAN BRETAGNA
Greater Manchester
ADDRESS: NOT PROVIDED - UK
ATLAS Study: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis -GB
Institution: Information not provided - UK
REGNO UNITO; GRAN BRETAGNA
Nottinghamshire
NOTTINGHAM
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)GB
LAM Action Nottingham, Voluntary Action Centre
Division of Respiratory Medicine, Clinical Sciences Building
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
PROTECT: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
NefIgArd: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
GALACTIC-1: A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
ARTEMIS - IGAN: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
RENEW: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
EPPIK: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - ES
Institution: Information not provided - ES
STATI UNITI
Michigan
DETROIT
Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study - US
Wayne State University
STATI UNITI
Texas
DALLAS
LEAP: A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 (Phase II) - US
Baylor University Medical Center
Institute of Metabolic Disease
SVEZIA
Region Stockholm
HUDDINGE
SAINT - Surfactant Administration by Insure or Thin Catheter - SE
Karolinska Institutet - Huddinge
Department of Clinical Science, Intervention and Technology (CLINTEC)
SVIZZERA
Suisse Alémanique
ZÜRICH
Surfactant Nebulization for the Early Aeration of the Preterm Lung: a Single Blinded, Parallel, Randomized Controlled Trial
Universitätspital Zürich
Klinik für Neonatologie
SVIZZERA
Suisse Alémanique
ZÜRICH
The FUNK-FLOW Study - Functional Residual Capacity During Different Levels of High-flow in Preterm Infants
Universitätspital Zürich
Klinik für Neonatologie
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFN?) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH(MAS/sHLH)-GB
Institution: Information not provided - CH
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU
Institution: Information not provided - AU
AUSTRIA
STEIERMARK
GRAZ
ANCA_CGM: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis (phase 4)
Medizinische Universität Graz
Klinische Abteilung für Nephrologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-BALM: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthritis (sJIA) (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PEAPOD: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis - AT
Institution: Information not provided - AT
BELGIO
OOST-VLAANDEREN
GENT
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - BE
Ghent University Hospital - UZ Gent
Reumatologie kinderen
BELGIO
VLAAMS BRABANT
LEUVEN
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency - BE
UZ Leuven - Campus Gasthuisberg
Centrum metabole ziekten - UZ Leuven
BULGARIA
South-West region
SOFIA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology
FRANCIA
ILE-DE-FRANCE
CLICHY
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - FR -
CHU Paris Nord-Val de Seine - Hôpital Beaujon
Service de médecine interne
FRANCIA
ILE-DE-FRANCE
LE KREMLIN-BICÊTRE
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis (Phase I) - FR
APHP. Université Paris-Saclay, Hôpital Bicêtre
Service de Rhumatologie pédiatrique
FRANCIA
ILE-DE-FRANCE
PARIS
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis. An International Randomised Controlled Trial (phase III) - FR
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
FRANCIA
ILE-DE-FRANCE
PARIS
AJIBIOREM : Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy (Phase III)
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique - Rhumatologie
FRANCIA
ILE-DE-FRANCE
PARIS
Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR
Hôpital Necker-Enfants Malades
Service de Génétique Moléculaire
GERMANIA
Baden-Württemberg
FREIBURG
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Sektion für Pädiatrische Infektiologie und Rheumatologie der Klinik für Allgemeine Kinder- und Jugendmedizin
GERMANIA
Bayern
GARMISCH-PARTENKIRCHEN
ß-SPECIFIC 4 Patients: An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III) - DE
Kinderklinik Garmisch-Partenkirchen gGmbH
Deutsches Zentrum für Kinder- und Jugendrheumatologie
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis -DE-
Institution: Information not provided - DE
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase (Phase II) -DE-
Institution: Information not provided - DE
GERMANIA
Berlin
BERLIN
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - DE
Deutsches Rheuma-Forschungszentrum Berlin
Forschungsbereich Epidemiologie
GERMANIA
Berlin
BERLIN
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - DE
HELIOS Klinikum Berlin-Buch
Klinik für Kinder- und Jugendmedizin
GERMANIA
Bremen
BREMEN
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - DE
Klinikum Bremen-Mitte
Eltern-Kind-Zentrum Prof. Hess
GERMANIA
Hamburg
HAMBURG
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - DE
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie
GERMANIA
Nordrhein-Westfalen
SANKT AUGUSTIN
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - DE
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin
GERMANIA
Rheinland-Pfalz
MAINZ
ASCEND: A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeatdose, dose-comparison study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency - DE
Universitätsmedizin Mainz
Villa Metabolica - Schwerpunktbereich angeborene Stoffwechselerkrankungen
ISRAELE
ISRAEL
PETAH TIKVA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute
ITALIA
CAMPANIA
NAPOLI
Valutazione dell'efficacia e del trattamento con Miglustat in pazienti affetti da malattia di Niemann-Pick di tipo c
Azienda Ospedaliera Universitaria "Federico II"
Laboratorio Dipartimento di Pediatria
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di estensione a lungo termine per valutare la sicurezza e l'efficacia di Tocilizumab sottocutaneo in pazienti con decorso poliarticolare e artrite idiopatica giovanile sistemica - IT
Institution: Information not provided - IT
ITALIA
FRIULI VENEZIA GIULIA
UDINE
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - IT -
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare
ITALIA
PUGLIA
BARI
Terapia combinata della crioglobulinemia mista HCV-correlata con Interferone-alpha pegilato, ribavirina e rituximab
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
LIBANO
Beyrouth
BEIRUT
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology
PAESI BASSI
Noord-Holland
AMSTERDAM
ASCEND: A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAESI BASSI
Utrecht
UTRECHT
B-Vit in JIA: Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment
UMC Utrecht - Universitair Medisch Centrum Utrecht
Kinderreumacentrum
PAESI BASSI
Utrecht
UTRECHT
VAART trial: Multicenter randomized clinical intervention trial in Patients with Juvenile Idiopathic Athritis (JIA) - Safety and efficacy of vaccination with live attenuated Measles-Mumps-Rubella vaccine
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Utrecht
UTRECHT
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Utrecht
UTRECHT
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety and Clinical Benefit of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Utrecht
UTRECHT
Beta-SPECIFIC 3: An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Utrecht
UTRECHT
Beta-SPECIFIC 4Pa: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Utrecht
UTRECHT
ESTIS trial: Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
PAESI BASSI
Zuid-Holland
LEIDEN
CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiopathic Arthritis (Phase IV).
LUMC - Leids Universitair Medisch Centrum
Willem-Alexander Kinderziekenhuis
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency - UK
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College London, main campus
Imperial College London Headquarters
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College NHS Trust
REGNO UNITO; GRAN BRETAGNA
Merseyside
LIVERPOOL
REPUBBLICA CECA
Capital City Prague
PRAHA
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
National Centre for Treatment of Gaucher Disease
SLOVACCHIA
Bratislavsky kraj
ADDRESS: NOT PROVIDED - SK
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK
Institution: Information not provided - SK
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
Efficacy, safety, tolerability and pharmacokinetics of tofacitinib for treatment of systemic juvenile idiopathic arthritis (sjia) with active systemic features in children and adolescent subjects - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
JUVE-BRIGHT: An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
EMERALD: A two-cohort, open-label, single arm, multicenter study to evaluate [...] emapalumab in children and adults with macrophage activation syndrome (MAS) in Still's disease (including systemic juvenile idiopathic arthritis and Adult onset Still's disease) or with MAS in Systemic lupus erythematous - ES
Institution: Information not provided - ES
SPAGNA
Madrid
MADRID
ASCEND: A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeatdose, dose-comparison study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency - ES
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
STATI UNITI
Georgia
ATLANTA
STATI UNITI
New York
NEW YORK
ASCEND-Peds: A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency - US
Icahn School of Medicine at Mount Sinai
TUNISIA
TUNISIA
TUNIS
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie
TURCHIA
TURKEY
IZMIR
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) - FR
Institution: Information not provided - FR
FRANCIA
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN Study: A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANCIA
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Churg Strauss Syndrome Without Poor Prognosis Factors (Phase III)
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
GERMANIA
Baden-Württemberg
MANNHEIM
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) -DE-
Institution: Information not provided - DE
GERMANIA
Berlin
BERLIN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Charité - Universitätsmedizin Berlin
GERMANIA
Nordrhein-Westfalen
ESSEN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Essen
GERMANIA
Nordrhein-Westfalen
MÜNSTER
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Münster
GERMANIA
Sachsen
DRESDEN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANIA
Thüringen
JENA
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Jena
PAESI BASSI
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
PAESI BASSI
Utrecht
UTRECHT
GO KIDS: A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
SPAGNA
Cataluña
BARCELONA
ABROGATE: Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener's) - ES
Hospital Clínic de Barcelona
Sperimentazioni cliniche internazionali
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
King's College London
King's College London Headquarters
DANIMARCA
Jylland
ADDRESS: NOT PROVIDED - DK
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients IMPALA
Institution: Information not provided - DK
FINLANDIA
Finland
TURKU
TRAUMAKINE: Interferon-beta treatment of acute respiratory distress syndrome (ARDS)
Faron Pharmaceuticals Limited
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome)
Imperial College London, main campus
Imperial College London Headquarters
SVIZZERA
Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG
BELGIO
VLAAMS BRABANT
MECHELEN
FRANCIA
ILE-DE-FRANCE
EVRY
NET4CGD: Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)
Généthon
Centre de Recherche Généthon
GERMANIA
Rheinland-Pfalz
INGELHEIM AM RHEIN
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) (Phase III) coordination
Boehringer Ingelheim Pharma GmbH & Co. KG
Boehringer Ingelheim Pharma GmbH
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone
Institution: Information not provided - IT
REGNO UNITO; GRAN BRETAGNA
Essex
HARLOW
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants with Systemic Lupus Erythematosus (SLE)
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Limited
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis.
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
IPF-COMFORT: A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis.
King's College Hospital
Department of Respiratory Medicine
STATI UNITI
Massachusetts
CAMBRIDGE
STATI UNITI
New York
NEW YORK
STATI UNITI
New York
NEW YORK
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis (Phase II-III)
Pfizer, Inc.
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis
Institution: Information not provided - US
SVIZZERA
Suisse Alémanique
ALLSCHWIL
MUSIC: A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis (Phase II) (coordination)
Actelion Pharmaceuticals Ltd.
SVIZZERA
Suisse Alémanique
ALLSCHWIL
BUILD 3 - Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter double-blind randomized placebo-controlled, parallel group, event-driven, group sequential, phase III study (coordination)
Actelion Pharmaceuticals Ltd.
SVIZZERA
Suisse Alémanique
BASEL
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary Hypertension
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFN?) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH(MAS/sHLH)
Institution: Information not provided - CH
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PANORAMA: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone
Institution: Information not provided - CH
CANADA
Alberta
MOUNTAIN VIEW
PAESI BASSI
Noord-Holland
NAARDEN
PAESI BASSI
Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL
PAESI BASSI
Utrecht
WOERDEN
Oral Miglustat in Adult patients With Stable Type 1 Gaucher Disease (Phase III) (coordination)
Actelion Pharmaceuticals Nederland B.V.
PAESI BASSI
Zuid-Holland
LEIDEN
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis
LUMC - Leids Universitair Medisch Centrum
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) (Coordination)
Institution: Information not provided - UK
REGNO UNITO; GRAN BRETAGNA
Oxfordshire
BEGBROKE
STATI UNITI
Massachusetts
CAMBRIDGE
STATI UNITI
Pennsylvania
PHILADELPHIA
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) (coordination)
Hospital of the University of Pennsylvania
Rheumatology Division
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
Institution: Information not provided - US
SVIZZERA
Suisse Alémanique
BASEL
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
Beta-SPECIFIC 4Pa: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III)
Institution: Information not provided - CH
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever
Institution: Information not provided - CH
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH